Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTA4H | P09960 | 5/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | BAX | Q07812 | 1/20 | 0.34 |
| ▸ | MAOA | P21397 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 2/20 | 0.32 |
| ▸ | MGLL | Q99685 | 1/20 | 0.32 |
| ▸ | MAOB | P27338 | 1/20 | 0.31 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | GLA | P06280 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.30 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3028362 | 0.81 | SOS1 (0.34) | LTA4HMAOAKDM1AMAOBKDM4E | |
| SCHEMBL4009428 | 0.79 | LMNA (0.47) | LTA4H | |
| SCHEMBL3024881 | 0.79 | SLC6A2 (0.37) | MAOBKDM4EMAPTHTR1ASLC6A2 | |
| SCHEMBL4919339 | 0.77 | LTA4H (0.54) | LTA4HCA1CA2KDM4EMAPT | |
| SCHEMBL5563927 | 0.77 | LTA4H (0.37) | LTA4HCA1CA2MGLLMAOB | |
| SCHEMBL3992435 | 0.77 | ALDH1A1 (0.36) | LTA4HTSHRKDM1AMAOBMAPT | |
| SCHEMBL5739551 | 0.77 | CYP1A1 (0.35) | MAOBSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11568631 | 0.76 | LTA4H (0.48) | LTA4HTSHRCA1CA2NR1H2 | |
| SCHEMBL20833184 | 0.73 | LTA4H (0.39) | LTA4HTSHRNR1H2BAXMAOA | |
| SCHEMBL4392094 | 0.73 | ALDH1A1 (0.30) | MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2401650-A1 | ADVANCED ELECTRODE STRUCTURES AND ELECTROCHROMIC DEVICES | Ntera, Inc. (US) | 2012-01-04 | — | — | EP | claimed |
| WO-2010099147-A1 | ADVANCED ELECTRODE STRUCTURES AND ELECTROCHROMIC DEVICES | NTERA INC. (US) | 2010-09-02 | — | — | WO | claimed |
| US-7037931-B2 | Corticotropin releasing factor moderator; analgesics; drug abruse, drug dependency; schizophrenia | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-05-02 | — | — | US | claimed |
| JP-2006501194-A | — | — | 2006-01-12 | — | — | JP | claimed |
| EP-1525190-A1 | CCK-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-04-27 | — | — | EP | claimed |
| WO-2004007463-A1 | CCK-1 RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA, N.V. (BE) | 2004-01-22 | — | — | WO | claimed |
| US-20230024434-A1 | Methods for Developing Personalized Drug Treatment Plans and Targeted Drug Development Based on Proteomic Profiles | SOMALOGIC, INC. (US) | 2023-01-26 | — | — | US | disclosed |
| US-20180259533-A1 | METHODS FOR DEVELOPING PERSONALIZED DRUG TREATMENT PLANS AND TARGETED DRUG DEVELOPMENT BASED ON PROTEOMIC PROFILES | SOMALOGIC, INC. (US) | 2018-09-13 | — | — | US | disclosed |
| WO-2016170545-A1 | PROCESS FOR THE PREPARATION OF 1-[(3R)-3-[4-AMINO-3-(4-PHENOXYPHENVL)-1H- PVRAZOLO[3,4-D]PYRINIIDIN-1-Y1]-1-PIPERIDINVL]-2-PROPEN-1-ONE AND ITS POLYMORPHS THEREOF | MSN LABORATORIES PRIVATE LIMITED (IN) | 2016-10-27 | — | — | WO | disclosed |
| US-8343977-B2 | Substituted triazolo-pyrimidine compounds | ARQULE, INC. (US) | 2013-01-01 | — | — | US | disclosed |
| WO-2011082271-A2 | SUBSTITUTED TRIAZOLO-PYRIMIDINE COMPOUNDS | ARQULE, INC. (US) | 2011-07-07 | — | — | WO | disclosed |
| US-20110160226-A1 | Substituted Triazolo-Pyrimidine Compounds | ARQULE, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-7968591-B2 | 1,3-disubstituted 4-methyl-1H-pyrrole-2-carboxamides and their use in medicaments | GRUENENTHAL GMBH (DE) | 2011-06-28 | — | — | US | disclosed |
| WO-2000071514-A1 | α-AMINO-β-SULFONYL HYDROXAMIC ACID COMPOUNDS | G.D. SEARLE & CO. (US) | 2000-11-30 | — | — | WO | disclosed |
| EP-0942650-A1 | INSECTICIDAL AND MITICIDAL COMPOSITIONS | AMERICAN CYANAMID COMPANY (US) | 1999-09-22 | — | — | EP | disclosed |
| WO-1998023153-A1 | INSECTICIDAL AND MITICIDAL COMPOSITIONS | AMERICAN CYANAMID COMPANY (US) | 1998-06-04 | — | — | WO | disclosed |
| US-5182381-A | Intermediates for 3-keto-19-nor-Δ4,9 -steroids | ROUSSEL ULCAF (FR) | 1993-01-26 | — | — | US | disclosed |
| US-5064822-A | Antiglucocorticoid | ROUSSEL UCLAF (FR) | 1991-11-12 | — | — | US | disclosed |
| US-4540686-A | ANTIPROGESTERONES | ROUSSEL UCLAF (FR) | 1985-09-10 | — | — | US | disclosed |
| US-4477445-A | ANTIGLUCOCORTICOIDS | ROUSSEL UCLAF (FR) | 1984-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160226-A1 | Substituted Triazolo-Pyrimidine Compounds | TYMP, TK1, DPYD | LTA4H 3056/4885TSHR 2820/4885CA1 4640/4885 |
| US-20180259533-A1 | METHODS FOR DEVELOPING PERSONALIZED DRUG TREATMENT PLANS AND TARGETED DRUG DEVELOPMENT BASED ON PROTEOMIC PROFILES | TTR, TPX2, FABP1 | LTA4H 4181/4885TSHR 2563/4885CA1 4318/4885 |
| US-20230024434-A1 | Methods for Developing Personalized Drug Treatment Plans and Targeted Drug Development Based on Proteomic Profiles | TTR, TPX2, FABP1 | LTA4H 4181/4885TSHR 2563/4885CA1 4318/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.